stockportfolio.pro
Immix Biopharma, Inc. (IMMX)
Healthcare · Biotechnology · NasdaqCM
Immix Biopharma, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-1.15M | $-24.38M | $-8.23M | $-15.43M | $-21.61M | $-29.44M |
| Net margin | — | — | — | — | — | — |
Source: Immix Biopharma, Inc. SEC filings (10-K).
Explore 6 years of Immix Biopharma, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IMMX in your portfolio →
Immix Biopharma, Inc. financial history by metric
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Immix Biopharma, Inc. — frequently asked questions
What is Immix Biopharma, Inc.'s revenue?
Immix Biopharma, Inc. (IMMX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Immix Biopharma, Inc. profitable?
No — IMMX reported a net loss of $-29.44M in fiscal 2025.
What is IMMX's P/E ratio?
Immix Biopharma, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Immix Biopharma, Inc. have?
As of fiscal year 2025, IMMX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Immix Biopharma, Inc.'s market cap?
Immix Biopharma, Inc. (IMMX) has a market capitalization of about $587.67M, based on the latest data in our nightly-refreshed cache.
When does Immix Biopharma, Inc.'s fiscal year end?
IMMX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Immix Biopharma, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.